Oak Thistle LLC Invests $321,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Oak Thistle LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 553 shares of the medical research company’s stock, valued at approximately $321,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sugarloaf Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton raised its stake in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 19 shares in the last quarter. Tsfg LLC raised its stake in shares of Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 19 shares in the last quarter. Pacifica Partners Inc. raised its stake in shares of Thermo Fisher Scientific by 16.5% in the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 20 shares in the last quarter. Finally, Foundations Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Foundations Investment Advisors LLC now owns 1,069 shares of the medical research company’s stock valued at $591,000 after purchasing an additional 20 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 2.0 %

Shares of NYSE:TMO traded down $11.28 during mid-day trading on Monday, hitting $541.72. The stock had a trading volume of 1,458,657 shares, compared to its average volume of 1,551,050. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a market cap of $206.79 billion, a PE ratio of 34.75, a P/E/G ratio of 2.58 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company’s 50 day moving average is $574.84 and its 200-day moving average is $563.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $607.06.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.